These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 29684379)

  • 1. Effect of a long-term treatment with metformin in dystrophic mdx mice: A reconsideration of its potential clinical interest in Duchenne muscular dystrophy.
    Mantuano P; Sanarica F; Conte E; Morgese MG; Capogrosso RF; Cozzoli A; Fonzino A; Quaranta A; Rolland JF; De Bellis M; Camerino GM; Trabace L; De Luca A
    Biochem Pharmacol; 2018 Aug; 154():89-103. PubMed ID: 29684379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points.
    Capogrosso RF; Mantuano P; Cozzoli A; Sanarica F; Massari AM; Conte E; Fonzino A; Giustino A; Rolland JF; Quaranta A; De Bellis M; Camerino GM; Grange RW; De Luca A
    J Appl Physiol (1985); 2017 Apr; 122(4):828-843. PubMed ID: 28057817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
    Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
    J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteome analysis in dystrophic mdx mouse muscle reveals a drastic alteration of key metabolic and contractile proteins after chronic exercise and the potential modulation by anti-oxidant compounds.
    Gamberi T; Fiaschi T; Valocchia E; Modesti A; Mantuano P; Rolland JF; Sanarica F; De Luca A; Magherini F
    J Proteomics; 2018 Jan; 170():43-58. PubMed ID: 28966053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
    Nio Y; Tanaka M; Hirozane Y; Muraki Y; Okawara M; Hazama M; Matsuo T
    FASEB J; 2017 Dec; 31(12):5307-5320. PubMed ID: 28798156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
    St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
    Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A long-term treatment with taurine prevents cardiac dysfunction in mdx mice.
    Mele A; Mantuano P; De Bellis M; Rana F; Sanarica F; Conte E; Morgese MG; Bove M; Rolland JF; Capogrosso RF; Pierno S; Camerino GM; Trabace L; De Luca A
    Transl Res; 2019 Feb; 204():82-99. PubMed ID: 30347179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing taurine intake and taurine synthesis improves skeletal muscle function in the mdx mouse model for Duchenne muscular dystrophy.
    Terrill JR; Pinniger GJ; Graves JA; Grounds MD; Arthur PG
    J Physiol; 2016 Jun; 594(11):3095-110. PubMed ID: 26659826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.
    Marrocco V; Fiore P; Benedetti A; Pisu S; Rizzuto E; Musarò A; Madaro L; Lozanoska-Ochser B; Bouché M
    EBioMedicine; 2017 Feb; 16():150-161. PubMed ID: 28089792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of resveratrol, apocynin and taurine on mechanical-metabolic uncoupling and oxidative stress in a mouse model of duchenne muscular dystrophy: A comparison with the gold standard, α-methyl prednisolone.
    Capogrosso RF; Cozzoli A; Mantuano P; Camerino GM; Massari AM; Sblendorio VT; De Bellis M; Tamma R; Giustino A; Nico B; Montagnani M; De Luca A
    Pharmacol Res; 2016 Apr; 106():101-113. PubMed ID: 26930420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melatonin improves muscle function of the dystrophic mdx5Cv mouse, a model for Duchenne muscular dystrophy.
    Hibaoui Y; Reutenauer-Patte J; Patthey-Vuadens O; Ruegg UT; Dorchies OM
    J Pineal Res; 2011 Sep; 51(2):163-71. PubMed ID: 21486366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy.
    Miglietta D; De Palma C; Sciorati C; Vergani B; Pisa V; Villa A; Ongini E; Clementi E
    Orphanet J Rare Dis; 2015 Aug; 10():101. PubMed ID: 26296873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial content is preserved throughout disease progression in the mdx mouse model of Duchenne muscular dystrophy, regardless of taurine supplementation.
    Barker RG; Wyckelsma VL; Xu H; Murphy RM
    Am J Physiol Cell Physiol; 2018 Apr; 314(4):C483-C491. PubMed ID: 29351413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of potential synergistic action of a combined treatment with alpha-methyl-prednisolone and taurine on the mdx mouse model of Duchenne muscular dystrophy.
    Cozzoli A; Rolland JF; Capogrosso RF; Sblendorio VT; Longo V; Simonetti S; Nico B; De Luca A
    Neuropathol Appl Neurobiol; 2011 Apr; 37(3):243-56. PubMed ID: 20618838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin
    Dong X; Hui T; Chen J; Yu Z; Ren D; Zou S; Wang S; Fei E; Jiao H; Lai X
    Front Physiol; 2021; 12():642908. PubMed ID: 34012406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-Dystroglycan Restoration and Pathology Progression in the Dystrophic
    Mantuano P; Boccanegra B; Conte E; De Bellis M; Cirmi S; Sanarica F; Cappellari O; Arduino I; Cutrignelli A; Lopedota AA; Mele A; Denora N; De Luca A
    Biomolecules; 2021 Nov; 11(11):. PubMed ID: 34827740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isometric resistance training increases strength and alters histopathology of dystrophin-deficient mouse skeletal muscle.
    Lindsay A; Larson AA; Verma M; Ervasti JM; Lowe DA
    J Appl Physiol (1985); 2019 Feb; 126(2):363-375. PubMed ID: 30571283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression in mdx mouse muscle in relation to age and exercise: aberrant mechanical-metabolic coupling and implications for pre-clinical studies in Duchenne muscular dystrophy.
    Camerino GM; Cannone M; Giustino A; Massari AM; Capogrosso RF; Cozzoli A; De Luca A
    Hum Mol Genet; 2014 Nov; 23(21):5720-32. PubMed ID: 24916377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy.
    Percival JM; Whitehead NP; Adams ME; Adamo CM; Beavo JA; Froehner SC
    J Pathol; 2012 Sep; 228(1):77-87. PubMed ID: 22653783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.